|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then showed that small molecule inhibition of PPARγ decreases the growth of AR-positive and -negative PC cells in vitro and that T0070907, a potent PPARγ antagonist, significantly decreased the growth of human PC xenografts in nude mice.
|
31769890 |
2020 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, two new studies, taking vastly different, unbiased approaches, have identified PPARγ as a target in prostate cancer and suggest that PPARγ inhibition might be useful in prostate cancer prevention and treatment.
|
28597850 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings strengthen the rationale for future efforts to determine whether targeting the PPARγ-adiponectin-MCP-1 axis will decrease periprostatic adipose inflammation and thereby reduce the risk of high-grade prostate cancer or improve outcomes for men with prostate cancer.<i></i>.
|
29222347 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The link between prostate cancer (PC) development and lipid metabolism is well established, with AR intimately involved in a number of lipogenic processes involving SREBP1, PPARG, FASN, ACC, ACLY and SCD1.
|
29466694 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study also concluded that PPARγ may be used as a potential remedial target for the prevention and treatment of prostate cancer cell invasion and metastasis.
|
30250621 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BMP2, PPARG and PRKAR2B genes may therefore be potential biomarkers in the treatment of PCa.
|
28800317 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data show that warfarin inhibits PPARγ and AR signaling, which suggests that inhibition of these pathways could be used to reduce the risk of developing prostate cancer.
|
28099154 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further functionally characterise the FABP5-PPARγ-VEGF signal transduction pathway, we have, in this work, investigated the molecular mechanisms involved in its tumorigenicity promoting role in prostate cancer.
|
26814431 |
2016 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Also overexpression of AKR1C3 could result in the accumulation of prostaglandin F2α (PGF2α), which can not only promote prostate cancer cell 's proliferation but also could enhance prostate cancer cells resistance to radiation and activated the MAPK pathway and inhibited the expression of PPARγ.
|
27385003 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since 5-LO, mPGES1, PPARα, and PPARγ represent potential anti-cancer drug targets, we here investigated the effects of 39 pirinixic acid derivatives on prostate cancer (PC-3) and neuroblastoma (UKF-NB-3) cell viability and, subsequently, the effects of selected compounds on drug-resistant neuroblastoma cells.
|
26887049 |
2016 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The goal of this study was to examine whether the androgen receptor (AR) regulates PPARγ expression and function within human prostate cancer cells. qRT-PCR and Western blot analyses revealed nanomolar concentrations of the AR agonist dihydrotestosterone (DHT) decrease PPARγ mRNA and protein within the castration-resistant, AR-positive C4-2 and VCaP human prostate cancer cell lines.
|
26945682 |
2016 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that CaP patients could be stratified in terms of PPARG/FASN and PTEN levels to identify patients with aggressive CaP who may respond favorably to PPARG/FASN inhibition.
|
27357679 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have demonstrated that PPAR-γ ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects.
|
25931782 |
2015 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
|
25669987 |
2015 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to examine the association between PPARG Pro12Ala, NFKB1 -94 ins/del, NFKBIA -826C/T, COX-1 (50C>T), and COX-2 (-1195G>A) polymorphisms on prostate cancer risk.
|
26788504 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor γ ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway.
|
24787994 |
2014 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of C-FABP and PPARγ in prostate cancer cell lines and the cytoplasm and nuclei of carcinoma tissues were significantly (Student's t-test, p<0.05) higher compared to those in benign cell lines and BPH tissues.
|
24189640 |
2014 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aims of this study were 1) to evaluate whether polymorphisms and haplotypes of the inflammation-related genes COX-2, Il1B, NFKB1, and PPARG are associated with risk of PC; 2) to investigate gene-environment interactions between polymorphisms and NSAID use; and 3) to examine whether the studied polymorphisms were associated with the aggressiveness of PC.
|
23880210 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flow cytometry analyses showed that lycopene, in combination with chemotherapeutic agents and PPARγ agonists, induced modest cell cycle arrest with significant increase in cell death by apoptosis and necrosis on prostate cancer.
|
23746934 |
2013 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, exposure of prostate cancer cells to 15d-PGJ(2) does not simply evoke a general inhibition of nuclear receptor activity or transcription because under the same conditions, peroxisome proliferator-activated receptor-γ is activated by 15d-PGJ(2).
|
23192983 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As expected, lycopene treatment (2.5-10 μM) significantly inhibited the proliferation of LNCaP cells during incubation for 96 h. Lycopene significantly increased the protein and mRNA expression of PPARγ and LXRα at 24 and 48 h, while the increased in the expression of ATP-binding cassette transporter 1 (ABCA1) was only evident 96 h. In addition, lycopene significantly decreased cellular total cholesterol levels and increased apoA1 protein expression at 96 h. Incubation of LNCaP cells with lycopene (10 μM) in the presence (20 μM) of a specific antagonist of PPARγ (GW9662) and LXRα (GGPP) restored the proliferation of LNCaP cells to the control levels and significantly suppressed protein expression of PPARγ and LXRα as well as increased cellular total cholesterol levels.
|
21334870 |
2012 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show positive correlation between PPARγ and FASN protein in PCa cell lines and synergism between TZDs and FASN blockers in PCa cell viability reduction and apoptosis induction.
|
21170507 |
2011 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the mechanisms of the PPARγ agonist-induced prostate cancer cell growth inhibition, we examined the effect of troglitazone on the expression of PPARγ, GSK-3β and activity of NFκB as well as on the prostate cancer cell growth.
|
21613824 |
2011 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We genotyped men with localized/regional prostate cancer for 26 loci across eight genes that are central to cellular antioxidant defence: glutathione peroxidase (GPX1, GPX4), peroxisome proliferator-activated receptor γ coactivator (PPARGC1A, PPARGC1B), SOD1, SOD2, and SOD3, and 'X-ray repair complementing defective repair in Chinese hamster cell 1' (XRCC1).
|
20477822 |
2011 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
|
20932825 |
2010 |